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Abstract. Chronic treatment with amitriptyline produces dose-dependent super- 
sensitivity ofa central muscarinic cholinergic mechanism involved in the regulation 
of core body temperature. The authors demonstrated that chronic treatment with 
lithium prevents the induction of this response. The potential clinical and theoreti- 
cal significance of this finding is set forth. 
Key Words. Affective disorders, amitriptyline, cholinergic, depression, lithium, 
mania, muscarinic. 
Amitriptyline (AMI) produces dose-dependent supersensitivity of a central muscir- 
rinic mechanism (Dilsaver et al., 1987; Dilsaver and Snider, 1988). Paradoxically, 
supersensitivity of muscarinic systems is implicated in the pathophysiology of depres- 
sion (Janowsky et al., 1972; Dilsaver, 1986a-d). Lithium (Li’) potentiates (de Mon- 
tigny et al., 1983; Heninger et al., 1983) the therapeutic effects of tricyclic 
antidepressants (TCAs). Dilsaver (1984) proposed that Li+ might prevent the super- 
sensitization of muscarinic networks. This hypothesis was subjected to a test by 
measuring the influence of Li’ on the capacity of AM1 to affect supersensitivity to the 
hypothermic effects of oxotremorine. 
Methods 
The dependent variable in the experiments below is change in core temperature in response to 
oxotremorine (0X0). Core temperature was measured using a telemetric thermosensor, the 
model VM Mini-Mitter (Mini-Miter Co., Sun River, OR). These instruments, which were 
implanted into the peritoneal cavity of adult male Sprague-Dawley rats, emit radio waves at a 
rate propo tional to temperature. A transistor radio set to an AM frequency served as receiver. 
k, Time to mlt IO sounds was measured using a digital display stopwatch. This measure was 
converted to temperature using a linear regression equation derived by measuring the emission 
profile of each individual thermosensor ina temperature-controlled water bath. This procedure 
is sensitive to a 0.1 “C change in temperature (Tocco-Bradley et al., 1985). Dilsaver and 
Majchrzak (in press) established the reliability and validity of this methodology, in psycho- 
pharmacological research paradigms. 
OX0 challenges were started between 9 and 10 a.m., 17 hours after the evening dose of AMI 
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and/ or LiCl. Methylscopolamine nitrate, 1 mg/ kg i.p., was given 30 min before the injection of 
OX0 to block its peripheral effects. Baseline temperature was measured 30 min after injecting 
methylscopolamine. Baseline core temperature was defined as the postmethylscopolamine 
measurement. This was the measure of core temperature (before OX0 challenge) used in the 
data analysis. OX0 was given after the measurement of baseline temperature. Temperature was 
recorded every 10 min for 120 min after the injection of 0X0. Core temperature was measured 
at baseline (before the injection of 0X0) and every 10 min thereafter for 120 min. The mean 
thermic response is the average of the 12 measurements 10, 20,30, . . . . 120 min following the 
injection of OX0 relative to baseline. Two doses of 0X0, 1 mg/ kg and 0.25 mg/ kg i.p., were 
used. The use of two doses of a drug allows one to illustrate that an effect is not peculiar to a 
given dose. 
OX0 (base), AMI HCI, and scopolamine methylnitrate were purchased from Sigma Chemi- 
cal Company (St. Louis, MO). Lithium chloride (LiCl) was obtained from Fisher Scientific. 
Doses of OX0 refer to the base form. Doses of all other drugs are expressed as the salt form. All 
drugs were given intraperitoneally (i.p.) on a milligram per kilogram (mg/ kg) basis. The doses 
of LiCl and AM1 were always 160 mg/ kg (3.77 mEq/ kg) and 10 mg/ kg i.p. These drugs were 
always given at 9 a.m. and 5 p.m. 
Data were assessed for significance using Student’s paired t test. The mean hypothermic 
response of each animal entered into the calculation oft statistics. Measures of variance refer to 
the standard deviation. 
Peak and trough plasma levels of Li’ were measured in separate groups of Sprague-Dawley 
rats given LiCl, 160 mg/ kg i.p., for 7 and 14 days. Blood was collected by cardiac puncture. 
Levels were determined by atomic absorption spectrophotometry in the Clinical Laboratory of 
the Department of Psychiatry at the University of Michigan. This assay has intra-assay and 
interassay coefficients of variation of 4.2% and S.%, respectively. 
Results 
Experiment 1 (Determination of plasma trough and peak Li’ levels after treatment 
with LiCl for 7 or 14 days): (1) Eleven (n = 11) rats weighing 232.7 f 15.6 g were treated 
with LiCl for 7 days. Blood was drawn 16 hours after the 14th dose on day 8 by cardiac 
puncture for the measurement of the trough Li’ level. (2) Nine (n = 9) rats weighing 
228.3 ? 15.9 g were similarly treated. These animals were individually given LiCl, 160 
mg/ kg i.p., at 2-min intervals between 8:50 a.m. and 9: 10 a.m. on day 8. Blood was 
drawn 60 min after injection for determination of peak plasma levels. (3) Trough levels 
were measured in 16 rats weighing 267.5 f 15.2 g treated with LiCl for 14 days. Blood 
was drawn 16 hours after the 28th dose of Li’. (4) Eleven (n= 11) rats weighing 254.6 f 
24.5 g were given LiCl for 14 days. Blood was collected in the manner described above 
for determination of peak Li’ levels. 
The mean peak and 16 hour trough Li’ levels following 7 days of treatment with 
LiCl were 3.10 * 0.39 (n = 9) and 0.25 * 0.10 (n = 11) mEq/l, respectively. The 
corresponding levels after 14 days of treatment were 3.3 1 f 0.76 mEq/ 1 (n = 11) and 
0.72 f 0.20 mEq/ 1 (n = 16), respectively. These results are also presented in Table 1. 
Experiment 2 (Illustration that Li+ blocks the capacity of AMI to produce 
supersensitivity to 0X0): LiCl, 160 mg/ kg i.p., was given to six rats weighing 346.7 f 
9. I for 7 days. On the morning of the 8th day (18 hours after the last dose of LiCl), the 
animals were challenged with 0X0, 1 mg/ kg i.p. The rats were then treated with a 
combination of LiCl and AMI, 10 mg/ kg i.p., for 7 days. The hypothermic response to 
OX0 was measured on the morning of the 15th day. This experiment assessed whether 
treatment with Li’ followed by concurrent treatment with Li’ and AMI is associated 
with a lack of supersensitization to the thermic effects of 0X0. 
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Table 1. Peak and trough lithium levels (Experiment 1) 
Treatment Type of Level1 
with LiCP level n (mW) 
7 days Trough 
7 days Peak 
14 days Trough 
14 days Peak 
1. Mean + SD. 
2.160 mg/kg at 9 a.m. and 5 p.m. 
11 0.25 2 0.10 
9 3.1 + 0.39 
11 3.31 + 0.76 
16 0.72 ? 0.20 
Mean core temperature of the sample at baseline was 37.1 f 0.5 “C. The mean 
thermic response to 0X0, 1 mg/ kg i.p., at baseline was -1.4 f 1.0 “C. The thermic 
response to 0X0, 1 mg/ kg i.p., after 7 days of treatment with Li’ alone was -1.3 f 0.7 
o C (net change in core = 0.1 ‘C, t = 0.25, df= 5,p> 0.8). Thus, treatment with LiCl did 
not alter the thermic response to 0X0. 
This sample used in this experiment began concurrent treatment with LiCl and AMI 
following 7 days of treatment with LiCl. The mean thermic response to OX0 after 1 
week of concurrent treatment was -0.90 f 0.8 ‘C. This did not differ from the response 
exhibited during treatment with LiCl alone (t = 0.85, df = 5, p > 0.40). This is 
remarkable given that the regularly recurring effect of treatment with AMI (10 mg/ kg 
i.p. twice daily) is the development of supersensitivity to OX0 (Dilsaver et al., 1987; 
Dilsaver and Snider, 1988). 
Experiment 3 (Illustration that the concurrent administration of Li’ blocks the 
capacity of AMI to produce supersensitivity to 0X0): This experiment involved the 
co-administration of LiCl and AMI to seven rats weighing 341.1 f 29.1 g. The animals 
were challenged with 0X0, 1 mg/ kg, before and after 1 week ofconcurrent treatment 
with Li’ and AMI. 
Mean core temperature of the sample at baseline was 37.8 f 0.5 “C. The baseline 
thermic response to 0X0, 1 mg/ kg i.p., was - 1.4 f 0.9 ‘C (n= 7). The sample exhibited 
a mean thermic response of -1 .O * 2.38 ’ C after 1 week of concurrent treatment with 
LiCl and AM1 (t ~0.47, df=6,p> 0.65). Thus, the simultaneous treatment of rats with 
LiCl and AM1 was not associated with the development of supersensitivity to 0X0. 
Experiment 4 (Illustration that chronic treatment with AM1 produces super- 
sensitivity to 0X0): This involved the administration of AM1 to 10 rats weighing 
272.5 f 18.3 g. These rats were challenged with 0X0, 0.25 mg/ kg, before treatment 
with AMI and on the morning of the 8th day of the experiment (i.e., 18 hours after the 
last dose of AMI). The objective was to demonstrate that treatment with AMI 
produces supersensitivity to 0X0. 
Mean core temperature at baseline was 37.0 * 0.3 “C. Before treatment, the sample 
exhibited a mean thermic response to OX0 of a.3 f 0.79 ‘C. One week of treatment 
with AM1 increased the thermic response to -1.1 *0.6”C(t = 3.65, df= 9,p<O.O06). 
Thus, treatment with AM1 produced supersensitivity to 0X0. 
Experiment 5 (Illustration that chronic treatment with Li+ blocks the capacity of 
AM1 to produce supersensitivity to OX0 using a second dose of 0X0): LiCl and AM1 
were simultaneously given to 13 rats weighing 243.5 f 3 1.4 g. The objective was to 
demonstrate that concurrent treatment with Li’ blocks the capacity of AM1 to 
produce supersensitivity to 0X0, 0.25 mg/ kg. 
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Mean core temperature of the sample at baseline was 37.7 + 0.7 “C. The mean 
thermic response to 0X0, 0.25 mg/ kg i.p., before treatment was -0.9 f 0.54 o C. The 
sample exhibited a mean thermic response of -0.8 + 0.7 “C 1 week after concurrent 
treatment with AMI and Li’. This did not differ from the response to OX0 before 
treatment (t q 0.22, df= 1 I, p > 0.80). 
Experiment 6 (Illustration that Li+ does not alter the thermic response to 0X0): 
The objective of this experiment was to demonstrate that treatment with Li’ does not 
alter the thermic response to 0X0. LiCl was given to rats weighing 250.0 + 19.0 (n = 
10). These animals were challenged with OX0 (base), 0.25 mg/ kg i.p., before and after 
7 days of treatment. 
Mean core temperature at baseline was 38.2 f 0.41 “C. The mean thermic response 
to 0X0, 0.25 mg/ kg, was -0.70 ? 0.79 ‘C. The mean response to OX0 following 1 
week of treatment with Li+ was -0.56 f 1 .O “C (t = 0.75, df = 9, p > 0.47). Thus, 
treatment with Li’ alone did not alter the thermic response to 0X0. 
Table 2 outlines the effects of the various treatments on the thermic response to 
0x0. 
Table 2. Effects of various treatments on thermic response to oxotremorine 
WO) 
Mean Mean % of 
core hypo- hypothermic 
tempera- thermic response 
ture at response to to 0x0 
Experi- baseline Pre- 0x0 OX0 at relative to 
ment (“C) treatment Treatment doss baseline (“C) baseline p 
2 37.1 f 0.5 Li Li+AMI 1.0 1.4 f 1.0 64.3% >0.40 
3 37.8 k 0.5 None LifAMl 1 .o 1.4 + 0.9 71.4% >0.65 
4 37.0 + 0.3 None AMI 0.25 0.3 + 0.79 366.7% <0.006 
5 37.7 f 0.7 None Li+AMI 0.25 0.9 f 0.54 88.9% >0.80 
6 38.2 f 0.41 None Li 0.25 0.7 f 0.79 80.0% >0.47 
Note. Table 2 presents the results of treating rats with lithium (LI’) for 1 week followed by the simultaneous administra- 
tion of Lit and amitriptyline (AMI) for 1 week (OX0 dose 1.0 mgikg i.p.) (Experiment 2) lithium and AMI simultaneously 
(Experiment 3) AMI alone (Experiment 4) Li’ and AMI simuftaneously (OX0 dose 0.25 mgikg i.p.) (Experiment 5) or Li’ 
alone (Experiment 6). Only the sample (Experiment 4) treated with AMI alone developed supersensitrvity to 0X0. Note 
that a hypothermic response of 1.4 + 1 .O”C (Experiment 2) is a thermic response of -1.4 f 1 .O”C. 
Discussion 
These data indicate that treatment with Li’, 3.77 mEq/ kg i.p. at 9 a.m. and 5 p.m., has 
no effect on the thermic response to 0X0, 1 .O mg/ kg i.p. (Experiment 2) or 0.25 
mg/ kg i.p. (Experiment 6). They also illustrate that treatment with AMI, 10 mg/ kg 
i.p. at 9 a.m. and 5 p.m., produces supersensitivity to the hypothermic effects of 0X0, 
0.25 mg/ kg i.p. (Experiment 4). We established that treatment with AMI produces 
dose-dependent supersensitivity of a central muscarinic mechanism to OX0 (Dilsaver 
et al., 1987; D&aver and Snider, 1988). Thus, the results reported in this article 
indicate that Li’ blocks the capacity of AMI to supersensitize this mechanism. 
Lerer (1985) reported that Li’ enhanced the hypothermic response to pilocarpine 
in rats treated with scopolamine. The study reported here is not a failure to replicate his 
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findings. Both AMI and scopolamine are muscarinic antagonists, but they do have 
unshared properties. For example, AM1 and its principal metabolite inhibit the 
reuptake of amines. It is conceivable that there is an interaction between Li+ and AM1 
which does not exist between scopolamine and Li’. 
Lerer (1985) gave scopolamine, 15 mg/ kg/day, by a osmotic mini-pump to rats. 
This is equivalent to 39 mM/ kg of scopolamine daily. In contrast, we injected AMI, 66 
mM/ kg/day. On a molar basis, our animals received 1.7 times more muscarinic 
receptor antagonist than did Lerer’s animals. However, Snyder and Yamamura (1977) 
estimated that the affinity of scopolamine for the muscarinic receptor (mAchR) in rat 
brain is 33.3 times greater than that of AMI. Thus, Lerer’s animals received a much 
higher dose of mAchR antagonist. This raises the possibility that Li’ might block the 
capacity of a lower dose of scopolamine to supersensitize the mAchR. It is important 
to note that the administration of Li’ by osmotic mini-pump results in a constant 
blood level of the mAchR antagonist. The mean Li’ blood level in Lerer’s sample was 
0.86 mEq/l (range 0.48-1.36 Eq/l). The administration of LiCl by a bolus injection 
twice daily results in a high peak level (> 3.1 mEq/ 1). This could affect the capacity of 
Li+ to stabilize the receptor. 
The findings reported here have potential clinical relevance. Reports indicate that 
Li+ potentiates the efficacy of tricyclic antidepressants (TCAs) (de Montigny et al., 
1983; Heninger et al., 1983; Charney et al., 1984, Price et al, 1984). Investigators have 
proposed that this is due to activation of presynaptic serotonergic mechanisms 
(Heninger et al., 1983; Charney et al., 1984). This may be a factor, but other effects of 
Li+ could be contributory. 
Chronic treatment with TCAs produces supersensitivity of a central muscarinic 
mechanism (Dilsaver et al., 1987; Dilsaver and Davidson, 1987; Dilsaver and Snider, 
1988). Hyperfunction of central muscarinic mechanisms may be involved in the 
biology of depression (Janowsky et al., 1972; Dilsaver, 1986a-6). Cohen and Baldessa- 
rini (1985) reported that some patients developed tolerance to the antidepressant 
effects of TCAs. The capacity of TCAs to supersensitize muscarinic mechanisms may 
exacerbate a pathophysiological defect underlying melancholia. The capacity of Li+ to 
block supersensitization of muscarinic mechanisms by TCAs could contribute to its 
capacity to potentiate their action. 
Levy et al. (1982) reported that Li+ prevents atropine-induced up-regulation of 
mAchRs in vivo. Pestronk and Drachman (1980) found that Li+ reduced the prolifera- 
tion of extrajunctional nicotinic receptors in denervated skeletal muscle in vivo. 
However, Tollefson and Senogles( 1983) concluded that Li+, 1 mEq/ 1 in vitro, caused a 
50% (p < 0.05) reduction in affinity and a 23% decrease (p < 0.10) in pmax of 
3H-quinuclidinyl benzilate binding sites in homogenates of the human caudate 
nucleus. Dilsaver (1984) thoroughly reviewed the often incongruous literature describ- 
ing the effects of Li+ on cholinergic mechanisms in vivo and in vitro. He proposed that 
in vivo studies simulating the clinical situation are of primary importance and sug- 
gested that if an agent which supersensitizes muscarinic mechanisms were coadminis- 
tered with Li’ that the latter would be revealed to stabilize the mAchR. The results 
obtained in the in vivo experiments reported here support this idea. 
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